Recent Analysts’ Ratings Changes for Twist Bioscience (TWST)

Twist Bioscience (NASDAQ: TWST) recently received a number of ratings updates from brokerages and research firms:

• 9/21/2026 – Twist Bioscience had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/18/2026 – Twist Bioscience had its “sell” rating reaffirmed by BWS Financial. They now have a $45.00 price target on the stock.
• 9/17/2026 – Twist Bioscience had its price target raised by Leerink Partners from $120.00 to $160.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Twist Bioscience is now covered by BWS Financial. They set a “sell” rating and a $45.00 price target on the stock.
• 9/9/2026 – Twist Bioscience is now covered by UBS Group AG. They set a “neutral” rating and a $144.00 price target on the stock.
• 8/24/2026 – Twist Bioscience had its “buy” rating reaffirmed by Guggenheim.
• 8/5/2026 – Twist Bioscience had its price target raised by Piper Sandler from $85.00 to $115.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Twist Bioscience had its price target raised by Robert W. Baird from $113.00 to $115.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – Twist Bioscience had its “buy” rating reaffirmed by TD Cowen.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 356,546 shares of Twist Bioscience stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the transaction, the chief executive officer owned 620,589 shares in the company, valued at $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at $10,402,335.08. This trade represents a 2.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 533,125 shares of company stock worth $78,901,809 over the last 90 days. Insiders own 3.08% of the company’s stock.

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.